No Need For A Machine Anymore Just Put It In Your Mouth Before Going To Bed And Your Snoring Will Stop

The idea of ​​taking a pill before bed, rather than a mask or device, was once considered unrealistic. But in the treatment of obstructive sleep apnea, that impossible feat is now closer to reality. A new oral drug is moving toward regulatory approval in the United States that experts believe could revolutionize the way sleep apnea is treated. The drug, developed by Cambridge-based biotech company Agnamed, is a combination of two already known drugs that work together to keep the muscles in the upper throat active during sleep, preventing the airway from collapsing and allowing breathing to continue. Unlike current treatments, it does not require a CPAP machine, mask or mechanical devices, and is simply taken before going to bed. Obstructive sleep apnea is a condition in which the throat muscles relax excessively during sleep. As a result, the airway repeatedly closes and breathing pauses. This not only disrupts sleep, but also increases the risk of heart disease, stroke, diabetes, and even neurological diseases like Alzheimer’s or Parkinson’s in the long term. Currently, CPAP machines are the most effective treatment for this disease. However, in reality, many patients cannot wear the mask or stop using it within a few days. As a result, sleep apnea still remains largely undiagnosed and untreated. Although an estimated 80 million people in the United States suffer from this disease, far fewer receive regular treatment. In India, this number is even more alarming, with various studies suggesting that about 104 million people are affected by obstructive sleep apnea. Sleep is a fundamental need for brain and body health. If you don’t get enough sleep every night, the effects can accumulate and become devastating. The possibility of a simple tablet for a disease that was once thought to be untreatable by medicine is truly a game-changer. Now all we have to do is wait for the final green light from the regulatory agency.

Thank you for reading this post, don't forget to subscribe!

read more